Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-Avibactam vs Meropenem for Nosocomial Infections in ACLF
NCT06818565Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Randomised, open-label trial of ceftazidime + avibactam in nosocomial infection (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients showing clinical response at Day 3. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
nosocomial infection
Beyond the preview
Go deeper on NCT06818565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818565.